Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 109

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Management Options for Irritable Bowel Syndrome

Camilleri, Michael·2018·Mayo Clinic Proceedings
DOI 10.1016/j.mayocp.2018.04.032
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2018.04.032

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 110

  1. Camilleri, 2014, Validating biomarkers of treatable mechanisms in irritable bowel syndrome, Neurogastroenterol Motil, 26, 1677, 10.1111/nmo.12421 · DOI
  2. Camilleri, 2015, Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders, Aliment Pharmacol Ther, 42, 818, 10.1111/apt.13351 · DOI
  3. Brierley, 2014, Neuroplasticity and dysfunction after gastrointestinal inflammation, Nat Rev Gastroenterol Hepatol, 11, 611, 10.1038/nrgastro.2014.103 · DOI · Paper page
  4. Julius, 2013, TRP channels and pain, Annu Rev Cell Dev Biol, 29, 355, 10.1146/annurev-cellbio-101011-155833 · DOI · Paper page
  5. Camilleri, 2017, Invited Review: Pharmacotherapy for irritable bowel syndrome, J Clin Med, 6, E101
  6. Chang, 2014, American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome, Gastroenterology, 147, 1149, 10.1053/j.gastro.2014.09.002 · DOI
  7. Ford, 2014, American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation, Am J Gastroenterol, 109, S2, 10.1038/ajg.2014.187 · DOI
  8. Spiller, 2007, Guidelines on the irritable bowel syndrome: mechanisms and practical management, Gut, 56, 1770, 10.1136/gut.2007.119446 · DOI · Paper page
  9. Camilleri, 2015, American College of Gastroenterology monograph on the management of irritable bowel syndrome, Expert Opin Pharmacother, 16, 629, 10.1517/14656566.2015.1002770 · DOI
  10. Ragnarsson, 1998, Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS): patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study, Eur J Gastroenterol Hepatol, 10, 415, 10.1097/00042737-199805000-00011 · DOI
  11. Sullivan, 1978, Colonic myoelectrical activity in irritable-bowel syndrome: effect of eating and anticholinergics, N Engl J Med, 298, 878, 10.1056/NEJM197804202981604 · DOI · Paper page
  12. Simrén, 2001, An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome, Gut, 48, 20, 10.1136/gut.48.1.20 · DOI
  13. David, 2014, Diet rapidly and reproducibly alters the human gut microbiome, Nature, 505, 559, 10.1038/nature12820 · DOI · Paper page
  14. Francis, 1994, Bran and irritable bowel syndrome: time for reappraisal, Lancet, 344, 39, 10.1016/S0140-6736(94)91055-3 · DOI
  15. Moayyedi, 2015, The effect of dietary intervention on irritable bowel syndrome: a systematic review, Clin Transl Gastroenterol, 6, e107, 10.1038/ctg.2015.21 · DOI
  16. Atkinson, 2004, Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial, Gut, 53, 1459, 10.1136/gut.2003.037697 · DOI · Paper page
  17. Young, 1994, A population study of food intolerance, Lancet, 343, 1127, 10.1016/S0140-6736(94)90234-8 · DOI · Paper page
  18. Bijkerk, 2009, Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial, BMJ, 339, b3154, 10.1136/bmj.b3154 · DOI
  19. Moayyedi, 2014, The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis, Am J Gastroenterol, 109, 1367, 10.1038/ajg.2014.195 · DOI
  20. Erdogan, 2016, Randomised clinical trial: mixed soluble/insoluble fibre vs. psyllium for chronic constipation, Aliment Pharmacol Ther, 44, 35, 10.1111/apt.13647 · DOI
  21. Tomlin, 1988, Laxative properties of indigestible plastic particles, BMJ, 297, 1175, 10.1136/bmj.297.6657.1175 · DOI
  22. Zimmerman, 2012, Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells, Am J Physiol Gastrointest Liver Physiol, 302, G1405, 10.1152/ajpgi.00543.2011 · DOI
  23. Lee, 2015, Beneficial effects of soy milk and fiber on high cholesterol diet-induced alteration of gut microbiota and inflammatory gene expression in rats, Food Funct, 6, 492, 10.1039/C4FO00731J · DOI
  24. Shepherd, 2008, Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence, Clin Gastroenterol Hepatol, 6, 765, 10.1016/j.cgh.2008.02.058 · DOI · Paper page
  25. Undseth, 2014, Abnormal accumulation of intestinal fluid following ingestion of an unabsorbable carbohydrate in patients with irritable bowel syndrome: an MRI study, Neurogastroenterol Motil, 26, 1686, 10.1111/nmo.12449 · DOI
  26. Staudacher, 2012, Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome, J Nutr, 142, 1510
  27. Halmos, 2014, A diet low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, 67, 10.1053/j.gastro.2013.09.046 · DOI · Paper page
  28. Böhn, 2015, Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, 1399, 10.1053/j.gastro.2015.07.054 · DOI · Paper page
  29. Varjú, 2017, Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies, PLoS One, 12, e0182942, 10.1371/journal.pone.0182942 · DOI
  30. Altobelli, 2017, Low-FODMAP diet improves irritable bowel syndrome symptoms: a meta-analysis, Nutrients, 9, 940, 10.3390/nu9090940 · DOI
  31. Krogsgaard, 2017, Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome, Aliment Pharmacol Ther, 45, 1506, 10.1111/apt.14065 · DOI
  32. 2015, Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance [correction], Br Med J, 350, h1216
  33. McKenzie, 2016, British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update), J Hum Nutr Diet, 29, 549, 10.1111/jhn.12385 · DOI · Paper page
  34. Vazquez Roque, 2013, A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function, Gastroenterology, 144, 903, 10.1053/j.gastro.2013.01.049 · DOI · Paper page
  35. Biesiekierski, 2013, No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates, Gastroenterology, 145, 320, 10.1053/j.gastro.2013.04.051 · DOI · Paper page
  36. Wahnschaffe, 2007, Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, 844, 10.1016/j.cgh.2007.03.021 · DOI
  37. Aziz, 2016, Efficacy of a gluten-free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype, Clin Gastroenterol Hepatol, 14, 696, 10.1016/j.cgh.2015.12.031 · DOI
  38. Shahabi, 2016, Self-regulation evaluation of therapeutic yoga and walking for patients with irritable bowel syndrome: a pilot study, Psychol Health Med, 21, 176, 10.1080/13548506.2015.1051557 · DOI · Paper page
  39. Kamiya, 2006, Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats, Gut, 55, 191, 10.1136/gut.2005.070987 · DOI · Paper page
  40. Niv, 2016, Randomized clinical study: partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome, Nutr Metab (Lond), 13, 10, 10.1186/s12986-016-0070-5 · DOI · Paper page
  41. Baştürk, 2016, Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial, Turk J Gastroenterol, 27, 439, 10.5152/tjg.2016.16301 · DOI
  42. Yuan, 2017, Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis, Curr Med Res Opin, 33, 1191, 10.1080/03007995.2017.1292230 · DOI
  43. Cayzeele-Decherf, 2017, Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis, World J Gastroenterol, 23, 336, 10.3748/wjg.v23.i2.336 · DOI
  44. Zhang, 2016, Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis, BMC Gastroenterol, 16, 62, 10.1186/s12876-016-0470-z · DOI
  45. Didari, 2015, Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis, World J Gastroenterol, 21, 3072, 10.3748/wjg.v21.i10.3072 · DOI · Paper page
  46. Whelan, 2014, Editorial: The importance of systematic reviews and meta-analyses of probiotics and prebiotics, Am J Gastroenterol, 109, 1563, 10.1038/ajg.2014.258 · DOI
  47. Madisch, 2001, A plant extract and its modified preparation in functional dyspepsia: results of a double-blind placebo controlled comparative study [in German], Z Gastroenterol, 39, 511
  48. Ammon, 2006, Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle, Phytomedicine, 13, 67, 10.1016/j.phymed.2006.08.004 · DOI
  49. Simmen, 2006, Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors, Phytomedicine, 13, 51, 10.1016/j.phymed.2006.03.012 · DOI
  50. Krueger, 2009, The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine, Neurogastroenterol Motil, 21, 1203-e110, 10.1111/j.1365-2982.2008.01242.x · DOI
  51. Madisch, 2004, Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial, Aliment Pharmacol Ther, 19, 271, 10.1111/j.1365-2036.2004.01859.x · DOI · Paper page
  52. Bensoussan, 1998, Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial, JAMA, 280, 1585, 10.1001/jama.280.18.1585 · DOI · Paper page
  53. Bensoussan, 2015, Efficacy of a Chinese herbal medicine in providing adequate relief of constipation-predominant irritable bowel syndrome: a randomized controlled trial, Clin Gastroenterol Hepatol, 13, 1946, 10.1016/j.cgh.2015.06.022 · DOI
  54. Leung, 2006, Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial, Am J Gastroenterol, 101, 1574, 10.1111/j.1572-0241.2006.00576.x · DOI
  55. Quartero, 2005, Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome, Cochrane Database Syst Rev, 2, (CD003460)
  56. Tack, 2006, Systematic review: the efficacy of treatments for irritable bowel syndrome—a European perspective, Aliment Pharmacol Ther, 24, 183, 10.1111/j.1365-2036.2006.02938.x · DOI
  57. Ford, 2008, Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis, BMJ, 337, a2313, 10.1136/bmj.a2313 · DOI · Paper page
  58. Hawthorn, 1988, The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations, Aliment Pharmacol Ther, 2, 101, 10.1111/j.1365-2036.1988.tb00677.x · DOI · Paper page
  59. Liu, 2013, TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain, Pain, 154, 2169, 10.1016/j.pain.2013.06.043 · DOI · Paper page
  60. Khanna, 2014, Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis, J Clin Gastroenterol, 48, 505, 10.1097/MCG.0b013e3182a88357 · DOI
  61. Cash, 2016, A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms, Dig Dis Sci, 61, 560, 10.1007/s10620-015-3858-7 · DOI
  62. Henningsen, 2003, Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review, Psychosom Med, 65, 528, 10.1097/01.PSY.0000075977.90337.E7 · DOI · Paper page
  63. Schmid, 2015, Placebo analgesia in patients with functional and organic abdominal pain: a fMRI study in IBS, UC and healthy volunteers, Gut, 64, 418, 10.1136/gutjnl-2013-306648 · DOI
  64. McQuay, 1996, A systematic review of antidepressants in neuropathic pain, Pain, 68, 217, 10.1016/S0304-3959(96)03140-5 · DOI · Paper page
  65. Saarto, 2007, Antidepressants for neuropathic pain, Cochrane Database Syst Rev, 4, (CD005454)
  66. Vahedi, 2005, The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study, Aliment Pharmacol Ther, 22, 381, 10.1111/j.1365-2036.2005.02566.x · DOI
  67. Vahedi, 2008, Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 27, 678, 10.1111/j.1365-2036.2008.03633.x · DOI
  68. Tabas, 2004, Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial, Am J Gastroenterol, 99, 914, 10.1111/j.1572-0241.2004.04127.x · DOI
  69. Tack, 2006, A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome, Gut, 55, 1095, 10.1136/gut.2005.077503 · DOI
  70. Vij, 1991, Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients, Indian J Psychiatry, 33, 243
  71. Brennan, 2009, Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study, Hum Psychopharmacol, 24, 423, 10.1002/hup.1038 · DOI
  72. Kaplan, 2014, An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder, Int J Psychiatry Clin Pract, 18, 11, 10.3109/13651501.2013.838632 · DOI · Paper page
  73. Lewis-Fernández, 2016, An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder, J Clin Psychopharmacol, 36, 710, 10.1097/JCP.0000000000000599 · DOI · Paper page
  74. Breining, 2017, Exposure to psychotropics in the French older population living with dementia: a nationwide population-based study, Int J Geriatr Psychiatry, 32, 750, 10.1002/gps.4517 · DOI
  75. Kasich, 1961, Treatment of diarrhea in irritable colon, including preliminary observations with a new antidiarrheal agent, diphenoxylate hydrochloride (Lomotil), Am J Gastroenterol, 35, 46
  76. Lavö, 1987, Loperamide in treatment of irritable bowel syndrome—a double-blind placebo controlled study, Scand J Gastroenterol Suppl, 130, 77, 10.3109/00365528709091003 · DOI
  77. Hovdenak, 1987, Loperamide treatment of the irritable bowel syndrome, Scand J Gastroenterol Suppl, 130, 81, 10.3109/00365528709091004 · DOI
  78. Efskind, 1996, A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome, Scand J Gastroenterol, 31, 463, 10.3109/00365529609006766 · DOI
  79. Dove, 2013, Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study, Gastroenterology, 145, 329, 10.1053/j.gastro.2013.04.006 · DOI
  80. Lee, 2005, Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 22, 981, 10.1111/j.1365-2036.2005.02685.x · DOI
  81. Iturrino, 2011, Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults, Am J Physiol Liver Physiol, 301, G377
  82. Houghton, 2007, Effect of a second-generation α2δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome, Gut, 56, 1218, 10.1136/gut.2006.110858 · DOI · Paper page
  83. Saito, 2016, A placebo-controlled trial of pregabalin for irritable bowel syndrome, Am J Gastroenterol, 111, S236, 10.14309/00000434-201610001-00521 · DOI
  84. Camilleri, 2018, Towards an effective peripheral visceral analgesic: responding to the national opioid crisis, Am J Physiol Gastrointest Liver Physiol, 314, G637, 10.1152/ajpgi.00013.2018 · DOI
  85. Berger, 2009, The expanded biology of serotonin, Annu Rev Med, 60, 355, 10.1146/annurev.med.60.042307.110802 · DOI · Paper page
  86. Gershon, 1990, 5-HT receptor subtypes outside the central nervous system: roles in the physiology of the gut, Neuropsychopharmacology, 3, 385
  87. Viramontes, 2001, Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 96, 2671, 10.1111/j.1572-0241.2001.04138.x · DOI
  88. Hicks, 2002, Excitation of rat colonic afferent fibres by 5-HT(3) receptors, J Physiol, 544, 861, 10.1113/jphysiol.2002.025452 · DOI
  89. Andresen, 2008, Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials, Clin Gastroenterol Hepatol, 6, 545, 10.1016/j.cgh.2007.12.015 · DOI
  90. Ford, 2009, Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am J Gastroenterol, 104, 1831, 10.1038/ajg.2009.223 · DOI · Paper page
  91. Fukudo, 2016, Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women, Gastroenterology, 150, 358, 10.1053/j.gastro.2015.10.047 · DOI · Paper page
  92. Matsueda, 2008, A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome, Scand J Gastroenterol, 43, 1202, 10.1080/00365520802240255 · DOI
  93. Garsed, 2014, A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut, 63, 1617, 10.1136/gutjnl-2013-305989 · DOI · Paper page
  94. Chang, 2006, Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-surveillance marketing data, Am J Gastroenterol, 101, 1069, 10.1111/j.1572-0241.2006.00459.x · DOI · Paper page
  95. Valentin, 2016, Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis, Gut, 65, 1951, 10.1136/gutjnl-2015-309889 · DOI
  96. Camilleri, 2015, Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 41, 438, 10.1111/apt.13065 · DOI
  97. Bajor, 2015, Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS, Gut, 64, 84, 10.1136/gutjnl-2013-305965 · DOI
  98. Acosta, 2016, Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome: a randomzed, double-blinded trial, Gastroenterology, 150, S948, 10.1016/S0016-5085(16)33204-8 · DOI
  99. Johanson, 2008, Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation, Am J Gastroenterol, 103, 170, 10.1111/j.1572-0241.2007.01524.x · DOI · Paper page
  100. Fukudo, 2015, Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation, Clin Gastroenterol Hepatol, 13, 294, 10.1016/j.cgh.2014.08.026 · DOI · Paper page
  101. Cryer, 2017, Analysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders, Dig Dis Sci, 62, 3568, 10.1007/s10620-017-4680-1 · DOI · Paper page
  102. Chey, 2012, Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety, Am J Gastroenterol, 107, 1702, 10.1038/ajg.2012.254 · DOI · Paper page
  103. Rao, 2012, A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation, Am J Gastroenterol, 107, 1714, 10.1038/ajg.2012.255 · DOI
  104. Shailubhai, 2011, Plecanatide, a guanylate cyclase C agonist, improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study, Am J Gastroenterol, 106, S502, 10.14309/00000434-201110002-01316 · DOI
  105. Fogel, 2017, Efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled clinical trials, Gastroenterology, 152, S1309, 10.1016/S0016-5085(17)34360-3 · DOI
  106. Layer, 2007, Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom, Ther Clin Risk Manag, 3, 107, 10.2147/tcrm.2007.3.1.107 · DOI
  107. Loughlin, 2010, Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study, J Cardiovasc Pharmacol Ther, 15, 151, 10.1177/1074248409360357 · DOI
  108. Nakamura, 2011, Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? a pilot study using the 5-HT4 receptor agonist mosapride, Hepatogastroenterology, 58, 453
  109. Mansour, 2012, A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome, Am J Gastroenterol, 107, 792, 10.1038/ajg.2012.26 · DOI
  110. Radziwon, 2017, Cognitive behavioral therapy for IBS: how useful, how often, and how does it work?, Curr Gastroenterol Rep, 19, 49, 10.1007/s11894-017-0590-9 · DOI

Cited by

See all 109

Metadata

Authors
Camilleri, M.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2018-12
Volume
93
Issue
12
Pages
1858-1872
ISSN
0025-6196
DOI
10.1016/j.mayocp.2018.04.032
Cited by
109
References
34
Language
en
Licence
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management Options for Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.1016/j.mayocp.2018.04.032
The paper
Camilleri, M. (2018). Management Options for Irritable Bowel Syndrome. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2018.04.032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.